Harness Therapeutics

Transine Therapeutics is a private biotechnology company headquartered in Cambridge, UK, focusing on developing a novel therapeutic RNA with the ability to upregulate protein expression at an unprecedented level of control and specificity: SINEUPs®. SINEUPs® bind to their target mRNA with high specificity and enhance protein levels by boosting protein translation. The attributes, versatility, specificity, and tunability of synthetic SINEUPs®, combined with safety controls, make the platform broadly applicable, with the potential to address diseases that cannot be treated by small molecules, traditional biologics, or gene therapies. Transine's technology significantly expands the druggable proteome and represents a completely unique mechanism of action for currently difficult-to-treat diseases. The modular nature of the technology allows Transine to rapidly design SINEUPs® with high specificity for almost any target where mRNA exists. The effect of SINEUPs® on translation is controlled, and the resulting increase in protein expression remains within physiological ranges. Their size is optimized to enable agnostic delivery methods for therapeutic SINEUPs®, including delivery as naked oligonucleotides or via viral vectors such as adeno-associated virus (AAV) or non-viral systems.